BDR Pharma launches generic antibiotic range medicine, Ceftazidime Avibactum

BDR Pharmaceuticals has launched a new generic in the antibiotic range: Ceftazidime + Avibactum. It will be effective in treating gram-negative infections (community-acquired pneumonia, intraabdominal infections and complicated UTIs).

XAVITAZ is a combination of 2 mg Ceftazidime and 500 mg Avibactam, this combination is useful in treating resistant gram-negative infections, including those caused by Pseudomonas aeruginosa, including many Ceftazidime-resistant strains.

XAVITAZ will help treat hospital-acquired pneumonia, the most common type of pneumonia in India, affecting 4 million people per year and hospitalising 20 per cent of them. Intra-abdominal infections, along with two other syndromes, accounted for 7.7 million deaths worldwide, in 2019.

Raheel Shah, Director of Business Development, BDR Group, stated, “Ensuring that all patients have access to quality-produced, world-class treatment was the main reason for launching the drug in India. BDR Pharma has a vision of strengthening the R&D department and works in accordance with the needs of the people. We are extremely pleased with the launch of Ceftazidime Avibactum because it will add to the repertoire of physicians treating infections.”